FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.
What happened
FDA inspected the K.C. Pharmaceuticals drug manufacturing facility in Pomona, CA, from January 20 to February 13, 2026. Investigators found the company kept making and releasing sterile drugs after its media fills (test batches made with growth medium instead of drug, used to prove the filling line stays sterile) failed on June 21, September 4 and November 4, 2024, and that operators breached the sterile barrier during filling. FDA also found inadequate airflow (smoke) studies, visual inspection that could not catch particles in the product, missing stability-indicating test methods, lab testing done without first checking the instruments worked, and weak quality-unit handling of complaints and stability testing.
What FDA found
The company had no adequate written procedures to prevent microbiological contamination of its sterile drugs, and it continued to make and release sterile products after media fill failures without timely, well-supported investigations or effective corrective actions.
21 CFR 211.113(b)Operators in the cleanest (ISO 5) filling areas leaned into the barrier system, handled parts without forceps and opened the barrier to reach difficult spots, and the company did not investigate what impact this had on the sterility of drugs already sold; its airflow (smoke) studies also could not show that air flowed correctly.
21 CFR 211.113(b)The visual inspection after filling was not good enough to find particles and foreign matter in every unit, and its sampling plan did not even include a defect category for particulates.
21 CFR 211.100(a)The company had not established stability-indicating test methods for its OTC products, so it could not show that test results stayed accurate over the product's shelf life.
21 CFR 211.166(a)The lab ran total organic carbon and conductivity tests without first checking that the analyzer was performing suitably for that day's testing.
21 CFR 211.160(b)The quality unit's written procedures were inadequate and not followed: complaint severity was judged by who complained rather than by risk, investigations were late or incomplete, and stability time points and tests were missed.
21 CFR 211.22(d)
What FDA wants
FDA asks for an action plan covering product quality and patient safety risks for the company's drugs in U.S. distribution, including possible customer notifications and recalls, plus independent assessments, contamination-hazard risk assessments, and corrective action plans for aseptic operations, visual inspection, stability testing, laboratory controls and the complaint system. The letter does not state a response deadline in the text provided.
Who should pay attention
- companies whose OTC products are made at this contract manufacturer
- distributors and retailers selling the affected OTC drug products
- other aseptic fillers that rely on media fills and smoke studies for sterility assurance
This is a summary. Read the original letter on fda.gov.